Cost-effectiveness of postremission intensive therapy in patients with acute leukemia

Annals of Oncology

Volumn 18, Issue 3, 2007, Pages 529-534

  Yu, Y B ^a,b   Gau, J P ^a,b   You, J Y ^a,b   Chern, H H ^a   Chau, W K ^a,b   Tzeng, C H ^a,b   Ho, C H ^a,b   Hsu, H C ^a,b  

^a TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^b NATIONAL YANG MING UNIVERSITY   (Taiwan)

Author keywords

Acute myelogenous leukemia; Allogeneic stem cell transplantation; Cost effectiveness; High dose arabinoside; Postremission therapy

Indexed keywords

ARABINOSIDE; BUSULFAN; CYCLOPHOSPHAMIDE; CYCLOSPORIN; DAUNORUBICIN; GRANULOCYTE COLONY STIMULATING FACTOR; IDARUBICIN; METHOTREXATE; MITOXANTRONE; RETINOIC ACID;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ADULT; AGED; ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; BLOOD TRANSFUSION; CANCER SURVIVAL; CHROMOSOME ANALYSIS; CONSERVATIVE TREATMENT; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG MEGADOSE; FEMALE; FOLLOW UP; GRAFT VERSUS HOST REACTION; HOSPITALIZATION COST; HUMAN; LEUKEMIA REMISSION; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; PRIORITY JOURNAL; PROGNOSIS; PROMYELOCYTIC LEUKEMIA; RISK FACTOR;

EID: 33847635748     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdl420     Document Type: Article

References (28)

1. Stone RM, O'Donnell MR, Mikkael A, Sekeres MA. Acute myeloid leukemia. Hematology 2004; 98-117.
2. Zittoun RA, Mandelli F, Willemze R et al. Autologous or allogeneic bone marrow transplantation compared with intensive chemotherapy in acute myelogenous leukemia: European Organization for Research and Treatment of Cancer (EORTC) and the Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto (GIMEMA) Leukemia Cooperative Groups. N Engl J Med 1995; 332: 217-223.
3. Harousseau JL, Cahn JY, Pignon B et al. Comparison of autologous bone marrow transplantation and intensive chemotherapy as postremission therapy in adult acute myeloid leukemia: The Groupe Ouest Est Leucemies Aigues Myeloblastiques (GOELAM). Blood 1997; 90: 2978-2986.
4. Burnett AK, Goldstone AH, Stevens RM et al. Randomised comparison of addition of autologous bone-marrow transplantation to intensive chemotherapy for acute myeloid leukaemia in first remission: Results of MRC AML 10 trial - UK Medical Research Council Adult and Children's Leukaemia Working Parties. Lancet 1998; 351: 700-708.
5. Cassileth PA, Harrington DP, Appelbaum FR et al. Chemotherapy compared with autologous or allogeneic bone marrow transplantation in the management of acute myeloid leukemia in first remission. N Engl J Med 1998; 339: 1649-1656.
6. Grimwade D, Walker H, Oliver F et al. The importance of diagnostic cytogenetics on outcome in AML: Analysis of 1,612 patients entered into the MRC AML 10 trial: The Medical Research Council Adult and Children's Leukaemia Working Parties. Blood 1998; 92: 2322-2333.
7. Slovak ML, Kopecky KJ, Cassileth PA et al. Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: A Southwest Oncology Group/Eastern Cooperative Oncology Group Study. Blood 2000; 96: 4075-4083.
8. Byrd JC, Mrozek K, Dodge RK et al. Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: Results from Cancer and Leukemia Group B (CALGB 8461). Blood 2002; 100: 4325-4336.
9. Burnett AK, Wheatley K, Goldstone AH et al. The value of allogeneic bone marrow transplant in patients with acute myeloid leukaemia at differing risk of relapse: Results of the UK MRC AML 10 trial. Br J Haematol 2002; 118: 385-400.
10. Suciu S, Mandelli F, de Witte T et al. Allogeneic compared with autologous stem cell transplantation in the treatment of patients younger than 46 years with acute myeloid leukemia (AML) in first complete remission (CR1): An intention-to-treat analysis of the EORTC/ GIMEMAAML-10 trial. Blood 2003; 102: 1232-1240.
11. Schlenk RF, Benner A, Hartmann F et al. Risk-adapted postremission therapy in acute myeloid leukemia: Results of the German multicenter AML HD93 treatment trial. Leukemia 2003; 17: 1521-1528.
12. Welch HG, Larson EB: Cost effectiveness of bone marrow transplantation in acute nonlymphocytic leukemia. N Engl J Med 1989; 321: 807-812.
13. Dufoir T, Saux MC, Terraza B et al. Comparative cost of allogeneic or autologous bone marrow transplantation and chemotherapy in patients with acute myeloid leukaemia in first remission. Marrow Transplant 1992; 10: 323-329.
14. Freeman M, Vose JM, Bennett CL et al. Costs of care associated with high-dose therapy and autologous transplantation for non-Hodgkin's lymphoma: Results from the University of Nebraska Medical Center 1989 to 1995. Bone Marrow Transplant 1999; 24: 679-684.
15. Bennett CL, Armitage JL, Armitage GO et al. Costs of care and outcome for high-dose therapy and autologous transplantation for lymphoid malignancies: Results from the University of Nebraska 1987 through 1991. J Clin Oncol 1995; 13: 969-973.
16. Chen CC, Yang CF, Yang MH et al. Pretreatment prognostic factors and treatment outcome in elderly patients with de novo acute myeloid leukemia. Ann Oncol 2005; 16: 1366-1373.
17. Hsu HC, Gau JP, Liu JM et al. Post-remission intensive consolidation with high-dose cytarabine-based chemotherapy and granulocyte colony-stimulatory factor in adults with acute myelogenous leukemia. Adv Ther 2001; 18: 67-74.
18. Gold MR, Siegel JE, Russell LB, Weinstein MC (eds): Cost-Effectiveness in Health and Medicine. New York, NY: Oxford University Press 1996.
19. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457.
20. Esperou H, Brunot A, Roudot-Thoraval F et al. Predicting the costs of allogeneic sibling stem-cell transplantation: Results from a prospective, multicenter, French study. Transplantation 2004; 77: 1854-1858.
21. Lee SJ, Klar N, Weeks JC, Antin JH. Predictive costs of stem cell transplantation. J Clin Oncol 2000; 18: 64-71.
22. Lee SJ, Klar N, Weeks JC, Antin JH. Predicting costs of stem-cell transplantation. J Clin Oncol 2000; 18: 64.
23. Cordonnier C, Maury S, Esperou H et al. Do minitransplants have minicosts? A cost comparison between myeloablative and nonmyeloablative allogeneic stem cell transplant in patients with acute myeloid leukemia. Bone Marrow Transplant 2005; 36: 649-654.
24. Farag SS, Ruppert AS, Mrózek et al. Outcome of induction and postremission therapy in younger adults with acute myeloid leukemia with normal karyotype: A Cancer and Leukemia Group B Study. J Clin Oncol 2005; 23: 482-493.
25. van Agthoven M, Groot MT, Verdonck LF et al. Cost analysis of HLA-identical sibling and voluntary unrelated allogeneic bone marrow and peripheral blood stem cell transplantation in adults with acute myelocytic leukaemia or acute lymphoblastic leukaemia. Bone Marrow Transplant 2002; 30: 243-251.
26. Lee SJ, Zahrieh D, Alyea EP et al. Comparison of T-cell-depleted and non-T-cell-depleted unrelated donor transplantation for hematologic diseases: Clinical outcomes, quality of life, and costs. Blood 2002; 100: 2697-2702.
27. Rizzo JD, Vogelsang GB, Krumm S et al. Outpatient-based bone marrow transplantation for hematologic malignancies: Cost saving or cost shifting? J Clin Oncol 1999; 17: 2811-2818.
28. Frohling S, Scholl C, Gilliland DG, Levine RL. Genetics of myeloid malignancies: Pathogenetic and clinical implications. J Clin Oncol 2005; 26: 6285-6295.